|
Mutation Information
|
Mutation Site
|
Y109I |
|
Mutation Type
|
Amino acid level |
|
Gene/Protein/Region Type
|
C |
|
Relevant Drug
|
ABI-H0731 |
Literature Information
|
PubMed PMID
|
32868329
|
|
Published Year
|
2020 |
|
Journal
|
Antimicrobial agents and chemotherapy |
|
Title
|
Preclinical Profile and Characterization of the Hepatitis B Virus Core Protein Inhibitor ABI-H0731. |
|
Author
|
Huang Q,Cai D,Yan R,Li L,Zong Y,Guo L,Mercier A,Zhou Y,Tang A,Henne K,Colonno R |
|
Evidence
|
Significant cross-resistance to all CIs is observed when T33N and Y118F substitutions are present, while more selective resistance is noted with substitutions such as G29G and Y109I/M (ABI-H0731) and P25A (GLS4).
|
|
|
HBV Mutation Detail Information